At a glance
ClinicalIndex Comparison RecordN/ACompleted· 58 enrolled
Drug / intervention
BEAM Protocol +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Versus CEM (Carboplatin, Etoposide, Melphalan) in Lymphoma Patients as a Conditioning Regimen Before Autologous Hematopoietic Cell Transplantation
In Brief
A clinical study evaluating BEAM Protocol and CEM protocol for Lymphoma. Completed, enrolled 58 participants across 1 site.
Detailed Summary
The proposed research aims to compare between BeEAM standard regimen and CEM as conditioning regimen in lymphoma patients in safety profile\& toxicity, infections (Febrile neutropenia) during transplant, time to engraftment (recovery not neutropenic), Length of stay at hospital, time to relapse, and other complications.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma
CountriesEgypt
Collaborators--
Timeline
N/ACompletedFinished
2023202420252026
Enrollment StartNov 2022
First PostedApr 2023
Primary CompletionDec 2023
TodayJul 2026
First PostedApr 14, 2023
Enrollment StartNov 11, 2022
Primary CompletionDec 30, 2023
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 3.2 years ago
Interventions
BEAM Protocoldrug
BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan)
CEM protocoldrug
CEM (Carboplatin, Etoposide, Melphalan)